Inmune Bio Stock Investor Sentiment

INMB Stock  USD 9.22  0.16  1.77%   
About 56% of all INmune Bio's investors are looking to take a long position. The analysis of the overall investor sentiment regarding INmune Bio suggests that some traders are interested. The current market sentiment, together with INmune Bio's historical and current headlines, can help investors time the market. In addition, many technical investors use INmune Bio stock news signals to limit their universe of possible portfolio assets.
  
over three months ago at investing.com         
Inmune Bio CFO buys 49k in company stock
Investing News at Macroaxis
over three months ago at investing.com         
Inmune Bio CEO acquires 98k in company stock
Investing News at Macroaxis
over three months ago at finance.yahoo.com         
INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimers Disease Tr...
Yahoo News
over three months ago at globenewswire.com         
INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimers Disease Tr...
Macroaxis News: globenewswire.com
over three months ago at news.google.com         
SEC Form 424B5 filed by INmune Bio Inc. - Quantisnow
Google News at Macroaxis
over three months ago at seekingalpha.com         
INmune Bio stock dips on 13M securities offering
seekingalpha News
over three months ago at finance.yahoo.com         
INmune Bio Announces 13.0 Million Registered Direct Offering
Yahoo News
over three months ago at globenewswire.com         
INmune Bio Announces 13.0 Million Registered Direct Offering
Macroaxis News: globenewswire.com
over three months ago at finance.yahoo.com         
INmune Bio, Inc.s top owners are individual investors with 44 percent stake, while 23 percent is hel...
Yahoo News
over three months ago at www.macroaxis.com         
Acquisition by Moss David J of 7690 shares of INmune Bio at 6.4 subject to Rule 16b-3
Macroaxis News
over three months ago at finance.yahoo.com         
INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference
Yahoo News
over three months ago at news.google.com         
INmune Bio shares get sector outperform rating on AD drug potential - Investing.com
Google News at Macroaxis
over three months ago at news.google.com         
INMB 3-Year EBITDA Growth Rate -17.50 percent - GuruFocus.com
Google News at Macroaxis
over three months ago at news.google.com         
Fermata Advisors LLC Buys 2,689 Shares of INmune Bio, Inc. - Defense World
Google News at Macroaxis
over six months ago at simplywall.st         
INmune Bio Second Quarter 2024 Earnings US0.51 loss per share
Simply Wall St News at Macroaxis
Far too much social signal, news, headlines, and media speculation about INmune Bio that are available to investors today. That information is available publicly through INmune media outlets and privately through word of mouth or via INmune internal channels. However, regardless of the origin, that massive amount of INmune data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of INmune Bio news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of INmune Bio relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to INmune Bio's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive INmune Bio alpha.

INmune Bio Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for INmune Stock analysis

When running INmune Bio's price analysis, check to measure INmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy INmune Bio is operating at the current time. Most of INmune Bio's value examination focuses on studying past and present price action to predict the probability of INmune Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move INmune Bio's price. Additionally, you may evaluate how the addition of INmune Bio to your portfolios can decrease your overall portfolio volatility.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Stocks Directory
Find actively traded stocks across global markets
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account